| Characters | Carbapenem resistant patterns | Total [No, (%)] | |||||||
| Imipenem | R | R | I | R | R | R | I | I | 46 (82.1) |
| Meropenem | R | I | R | I | I | S | I | S | 26 (46.4) |
| Ertapenem | R | R | R | I | S | S | R | R | 40 (71.4) |
| No. | 24 | 6 | 2 | 16 | 8 | 56 | |||
| ESBL and AmpC phenotypes [No, (%)] | |||||||||
| ESBL + AmpC | 15 (62.5) | 4 (66.7) | 1 (50.0) | 14 (87.5) | 6 (75.0) | 40 (71.4) | |||
| ESBLs | 2 (8.3) | 0 (0.0) | 1 (50.0) | 1 (6.3) | 1 (12.5) | 5 (8.9) | |||
| AmpC | 6 (25.0) | 1 (16.6) | 0 (0.0) | 0 (0.0) | 1 (12.5) | 8 (14.3) | |||
| Neither | 1 (4.2) | 1 (16.6) | 0 (0.0) | 1 (6.3) | 0 (0.0) | 3 (5.4) | |||
| AmpA gnes [No, (%)] | |||||||||
| blaTEM | 14 (58.3) | 5 (83.3) | 1 (50.0) | 8 (72.7) | 3 (100.0) | 2 (100.0) | 5 (71.4) | 1 (100.0) | 39 (69.6) |
| blaCTX-M3 | 0 (0.0) | 1 (16.7) | 1 (50.0) | 1 (9.1) | 0 (0.0) | 0 (0.0) | 1 (14.3) | 0 (0.0) | 4 (7.1) |
| blaCTX-M14 | 6 (25.0) | 2 (33.3) | 0 (0.0) | 4 (36.4) | 0 (0.0) | 0 (0.0) | 3 (42.9) | 1 (100.0) | 16 (28.6) |
| AmpC genes [No, (%)] | |||||||||
| blaDHA | 20 (83.3) | 6 (100.0) | 1 (50.0) | 11 (100.0) | 3 (100.0) | 2 (100.0) | 7 (100.0) | 1 (100.0) | 51 (91.1) |
| blaCMY2 | 5 (20.8) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (57.1) | 0 (0.0) | 10 (17.9) |
| ESBL and AmpC phenotype | Outmembrane protein deficiency | ||||||||
| OmpK35 | OmpK36 | OmpK35 + OmpK36 | Normal | Total | |||||
| ESBL + AmpC | 27 (67.5) | 0 (0.0) | 6 (15.0) | 7 (17.5) | 40 (55.6) | ||||
| ESBLs | 3 (60.0) | 0 (0.0) | 2 (40.0) | 0 (0.0) | 5 (7.1) | ||||
| AmpC | 4 (50.0) | 0 (0.0) | 4 (50.0) | 0 (0.0) | 8 (66.7) | ||||
| No | 2 (66.7) | 0 (0.0) | 0 (0.0) | 1 (33.3) | 3 (33.3) | ||||
| Total | 36 (64.3) | 0 (0.0) | 12 (21.4) | 8 (14.3) | 56 (34.4) | ||||